Biora Therapeutics (BIOR) Competitors $0.15 -0.01 (-6.08%) As of 03/28/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BIOR vs. PLRZ, PRFX, AKAN, EVAX, NCNA, CYCC, SXTC, PTIX, SHPH, and PALIShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Polyrizon (PLRZ), PainReform (PRFX), Akanda (AKAN), Evaxion Biotech A/S (EVAX), NuCana (NCNA), Cyclacel Pharmaceuticals (CYCC), China SXT Pharmaceuticals (SXTC), Protagenic Therapeutics (PTIX), Shuttle Pharmaceuticals (SHPH), and Palisade Bio (PALI). These companies are all part of the "pharmaceutical products" industry. Biora Therapeutics vs. Polyrizon PainReform Akanda Evaxion Biotech A/S NuCana Cyclacel Pharmaceuticals China SXT Pharmaceuticals Protagenic Therapeutics Shuttle Pharmaceuticals Palisade Bio Biora Therapeutics (NASDAQ:BIOR) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment. Do analysts rate BIOR or PLRZ? Biora Therapeutics currently has a consensus price target of $23.00, indicating a potential upside of 14,777.10%. Given Biora Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Biora Therapeutics is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Polyrizon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in BIOR or PLRZ? 43.7% of Biora Therapeutics shares are held by institutional investors. 51.1% of Biora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer BIOR or PLRZ? Biora Therapeutics received 8 more outperform votes than Polyrizon when rated by MarketBeat users. CompanyUnderperformOutperformBiora TherapeuticsOutperform Votes880.00% Underperform Votes220.00% PolyrizonN/AN/A Does the media prefer BIOR or PLRZ? In the previous week, Polyrizon had 9 more articles in the media than Biora Therapeutics. MarketBeat recorded 9 mentions for Polyrizon and 0 mentions for Biora Therapeutics. Polyrizon's average media sentiment score of 0.46 beat Biora Therapeutics' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media. Company Overall Sentiment Biora Therapeutics Neutral Polyrizon Neutral Is BIOR or PLRZ more profitable? Company Net Margins Return on Equity Return on Assets Biora TherapeuticsN/A N/A -332.47% Polyrizon N/A N/A N/A Which has stronger valuation & earnings, BIOR or PLRZ? Polyrizon has lower revenue, but higher earnings than Biora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiora Therapeutics$892K0.78-$124.11M-$13.04-0.01PolyrizonN/AN/AN/AN/AN/A SummaryBiora Therapeutics beats Polyrizon on 7 of the 10 factors compared between the two stocks. Remove Ads Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$995,000.00$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.017.2623.5818.74Price / Sales0.78218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.006.386.894.23Net Income-$124.11M$142.34M$3.20B$247.47M7 Day Performance18.56%-5.15%-3.06%-2.29%1 Month Performance23.29%-7.55%1.51%-5.81%1 Year Performance-98.59%-11.06%9.37%-0.96% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora Therapeutics1.7271 of 5 stars$0.15-6.1%$23.00+14,777.1%-98.6%$995,000.00$892,000.00-0.01120Upcoming EarningsPLRZPolyrizonN/A$0.75+34.2%N/AN/A$2.34MN/A0.00N/ANews CoverageGap DownHigh Trading VolumePRFXPainReform2.494 of 5 stars$2.62+1.6%$8.00+205.3%-70.2%$2.26MN/A-0.024Upcoming EarningsPositive NewsAKANAkandaN/A$1.57+2.6%N/A-84.7%$2.24M$2.51M0.00110Positive NewsEVAXEvaxion Biotech A/S2.5955 of 5 stars$1.85-2.1%$20.00+981.1%-89.0%$2.17M$3.30M-1.2860Short Interest ↓News CoverageNCNANuCana3.7847 of 5 stars$0.79+0.1%$25.00+3,064.6%-80.3%$2.09MN/A-0.0830Short Interest ↓CYCCCyclacel Pharmaceuticals3.0362 of 5 stars$0.32+1.3%$11.00+3,295.1%-85.8%$2.04M$74,000.00-0.0314Short Interest ↓Gap DownSXTCChina SXT Pharmaceuticals1.0503 of 5 stars$2.81+6.8%N/A-79.3%$2.03M$1.93M0.0090Short Interest ↓News CoveragePTIXProtagenic Therapeutics0.9039 of 5 stars$0.26-6.5%N/A-87.1%$2.02MN/A-0.212Short Interest ↑Gap DownSHPHShuttle Pharmaceuticals1.9623 of 5 stars$0.39-6.3%N/AN/A$1.94MN/A-0.105Positive NewsGap DownPALIPalisade Bio2.4045 of 5 stars$0.70-1.4%$23.00+3,181.0%-88.3%$1.94M$250,000.00-0.0510Earnings ReportShort Interest ↑ Remove Ads Related Companies and Tools Related Companies Polyrizon Competitors PainReform Competitors Akanda Competitors Evaxion Biotech A/S Competitors NuCana Competitors Cyclacel Pharmaceuticals Competitors China SXT Pharmaceuticals Competitors Protagenic Therapeutics Competitors Shuttle Pharmaceuticals Competitors Palisade Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOR) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
